Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Fast Track Articles
  5. Fast Track Article
image of A Mini Review on Effect of Corona Virus on Cancer Related to Lungs

Abstract

The emergence of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted cancer patients, particularly those with lung cancer. This review delves into the intersection of COVID-19 and lung cancer, addressing concerns regarding diagnosis, treatment, and outcomes. Research demonstrates that patient co-factors, including age, sex, blood type, and knowledge levels, are strongly associated with the severity and mortality of COVID-19 in lung cancer patients. Older age, male gender, and specific blood types correlate with worse results. Cancer patients, already immunocompromised, face heightened risks from COVID-19, with increased morbidity and mortality rates. The pandemic has necessitated rapid adjustments in oncological care, including telemedicine and altered treatment protocols. Vaccination tactics are essential, with effectiveness differing based on whether patients have gotten the initial dosage, second dose, or booster doses. Various vaccination forms, including mRNA vaccines, viral vector vaccines, and inactivated virus vaccines, have differing effectiveness profiles, particularly in immunocompromised persons. Booster dosages have shown improved immunity against developing variations such as Delta and Omicron. Lung cancer, the second most diagnosed cancer globally, presents diverse challenges due to its association with smoking and exposure to environmental carcinogens. Diagnosis relies on histological confirmation, with treatment decisions guided by disease staging and molecular profiling. Innovative diagnostic tools, such as molecular markers and genetic sequencing, enhance personalized treatment approaches. The pandemic's impact on cancer diagnosis and treatment pathways underscores the need for vigilant surveillance and adaptive strategies to ensure optimal patient care. This abstract encapsulates the critical considerations and evolving landscape of managing COVID-19 and lung cancer, emphasizing the importance of tailored approaches in navigating these intertwined health crises. The abstract summarizes the diagnostic and management approaches for lung cancer and COVID-19, highlighting key methods such as radiographic screening, liquid biopsy, sputum examination, and nucleic acid amplification tests for diagnosis. Treatment strategies for both conditions are discussed, emphasizing the challenges faced by lung cancer patients, particularly in the context of COVID-19 infections. The abstract also addresses the importance of early detection through biomarker discovery and the development of new therapies tailored to individual patients. Furthermore, prognostic and predictive biomarkers for lung cancer are identified, such as EGFR mutations and ALK rearrangements, which inform treatment decisions. The abstract underscores the need for comprehensive care strategies that consider the intersection of lung cancer and COVID-19, ensuring optimal outcomes for affected patients. Ultimately, care strategies must take consideration of patient co-factors like age, sex, blood group, and knowledge levels, as well as vaccine administration schedules like first doses, second doses, and booster shots and vaccine type reflections. The overall strategy aims to improve treatment and immunization efficacy, improving lung cancer outcomes during the COVID-19 pandemic.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975329337241224085220
2024-12-30
2025-01-19

  • From This Site

    /content/journals/covid/10.2174/0126667975329337241224085220
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sadhukhan P. Ugurlu M.T. Hoque M.O. Effect of COVID-19 on lungs: Focusing on prospective malignant phenotypes. Cancers 2020 12 12 3822 10.3390/cancers12123822 33352869
    [Google Scholar]
  2. Gosain R. Abdou Y. Singh A. Rana N. Puzanov I. Ernstoff M.S. COVID-19 and cancer: A comprehensive review. Curr. Oncol. Rep. 2020 22 5 53 10.1007/s11912‑020‑00934‑7 32385672
    [Google Scholar]
  3. Hasan M.N. Islam M.A. Sangkham S. Werkneh A.A. Hossen F. Haque M.A. Alam M.M. Rahman M.A. Mukharjee S.K. Chowdhury T.A. Hernández S.J.E. Jakariya M. Ahmed F. Bhattacharya P. Sarkodie S.A. Insight into vaccination and meteorological factors on daily COVID-19 cases and mortality in Bangladesh. Groundw. Sustain. Dev. 2023 21 100932 10.1016/j.gsd.2023.100932 36945723
    [Google Scholar]
  4. Cascella M. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls Treasure Island (FL) StatPearls Publishing 2023
    [Google Scholar]
  5. Joode d.K. Dumoulin D.W. Engelen V. Bloemendal H.J. Verheij M. Laarhoven v.H.W.M. Dingemans I.H. Dingemans A.C. van der Veldt A.A.M. Impact of the coronavirus disease 2019 pandemic on cancer treatment: The patients’ perspective. Eur. J. Cancer 2020 136 132 139 10.1016/j.ejca.2020.06.019 32683273
    [Google Scholar]
  6. Cavalcanti I.D.L. Soares J.C.S. Impact of COVID‐19 on cancer patients: A review. Asia Pac. J. Clin. Oncol. 2021 17 3 186 192 10.1111/ajco.13445 32970923
    [Google Scholar]
  7. Martin T.A. Cancer invasion and metastasis: Molecular and cellular perspective. Madame Curie Bio. Data. Landes Bioscience 2013
    [Google Scholar]
  8. Tsim S. O’Dowd C.A. Milroy R. Davidson S. Staging of non-small cell lung cancer (NSCLC): A review. Respir. Med. 2010 104 12 1767 1774 10.1016/j.rmed.2010.08.005 20833010
    [Google Scholar]
  9. Abdoli A. Falahi S. Kenarkoohi A. COVID-19-associated opportunistic infections: A snapshot on the current reports. Clin. Exp. Med. 2021 22 3 327 346 10.1007/s10238‑021‑00751‑7 34424451
    [Google Scholar]
  10. Rudin C.M. Reck M. Johnson M.L. Blackhall F. Hann C.L. Yang J.C.H. Bailis J.M. Bebb G. Goldrick A. Umejiego J. Ares P.L. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J. Hematol. Oncol. 2023 16 1 66 10.1186/s13045‑023‑01464‑y 37355629
    [Google Scholar]
  11. Bian D.J.H. Sabri S. Abdulkarim B.S. Interactions between COVID-19 and Lung Cancer: Lessons learned during the pandemic. Cancers 2022 14 15 3598 10.3390/cancers14153598 35892857
    [Google Scholar]
  12. Rolfo C. Meshulami N. Russo A. Krammer F. Sastre G.A. Mack P.C. Gomez J.E. Bhardwaj N. Benyounes A. Sirera R. Moore A. Rohs N. Henschke C.I. Yankelevitz D. King J. Shyr Y. Bunn P.A. Jr Minna J.D. Hirsch F.R. Lung cancer and severe acute respiratory syndrome coronavirus 2 infection: Identifying important knowledge gaps for investigation. J. Thorac. Oncol. 2022 17 2 214 227 10.1016/j.jtho.2021.11.001 34774792
    [Google Scholar]
  13. Islam M.A. A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety. Infect. Med. 2023 2 4 247 261 10.1016/j.imj.2023.08.005 38205179
    [Google Scholar]
  14. Islam M.A. Marzan A.A. Arman M.S. Shahi S. Sakif T.I. Hossain M. Islam T. Hoque M.N. Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents. Sci. Rep. 2023 13 1 18644 10.1038/s41598‑023‑45517‑1 37903828
    [Google Scholar]
  15. Afshar M.Z. Hosseinzadeh R. Barary M. Ebrahimpour S. Alijanpour A. Sayad B. Hosseinzadeh D. Miri S.R. Sio T.T. Sullman M.J.M. Chahhoud C.K. Babazadeh A. Challenges posed by COVID‐19 in cancer patients: A narrative review. Cancer Med. 2022 11 4 1119 1135 10.1002/cam4.4519 34951152
    [Google Scholar]
  16. Bungaro M. Passiglia F. Scagliotti G.V. COVID-19 and Lung Cancer: A comprehensive overview from outbreak to recovery. Biomedicines 2022 10 4 776 10.3390/biomedicines10040776 35453526
    [Google Scholar]
  17. Dingemans A.M.C. Soo R.A. Jazieh A.R. Rice S.J. Kim Y.T. Teo L.L.S. Warren G.W. Xiao S.Y. Smit E.F. Aerts J.G. Yoon S.H. Veronesi G. Cobelli D.F. Ramalingam S.S. Garassino M.C. Wynes M.W. Behera M. Haanen J. Lu S. Peters S. Ahn M.J. Scagliotti G.V. Adjei A.A. Belani C.P. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J. Thorac. Oncol. 2020 15 7 1119 1136 10.1016/j.jtho.2020.05.001 32422364
    [Google Scholar]
  18. Khatiwada S. Subedi A. Lung microbiome and coronavirus disease 2019 (COVID-19): Possible link and implications. Hum. Microbiome J. 2020 17 100073 10.1016/j.humic.2020.100073 32835135
    [Google Scholar]
  19. Gundavda M.K. Gundavda K.K. Cancer or COVID-19? A review of guidelines for safe cancer care in the wake of the pandemic. SN Compr. Clin. Med. 2020 2 12 2691 2701 10.1007/s42399‑020‑00632‑2 33251481
    [Google Scholar]
  20. Ludwig S. Zarbock A. Coronaviruses and SARS-CoV-2: A brief overview. Anesth. Analg. 2020 131 1 93 96 10.1213/ANE.0000000000004845 32243297
    [Google Scholar]
  21. Ruiz C.V.J. Montes I.R. Puerta P.J.M. Ruiz C. Rodríguez M.L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020 54 62 75 10.1016/j.cytogfr.2020.06.001 32513566
    [Google Scholar]
  22. Gupta I. Rizeq B. Elkord E. Vranic S. Moustafa A.A.E. SARS-CoV-2 infection and lung cancer: Potential therapeutic modalities. Cancers 2020 12 8 2186 10.3390/cancers12082186 32764454
    [Google Scholar]
  23. Tang G. Liu Z. Chen D. Human coronaviruses: Origin, host and receptor. J. Clin. Virol. 2022 155 105246 10.1016/j.jcv.2022.105246 35930858
    [Google Scholar]
  24. Marchenko V. Danilenko A. Kolosova N. Bragina M. Molchanova M. Bulanovich Y. Gorodov V. Leonov S. Gudymo A. Onkhonova G. Svyatchenko S. Ryzhikov A. Diversity of gammacoronaviruses and deltacoronaviruses in wild birds and poultry in russia. Sci. Rep. 2022 12 1 19412 10.1038/s41598‑022‑23925‑z 36371465
    [Google Scholar]
  25. Salzberger B. Buder F. Lampl B. Ehrenstein B. Hitzenbichler F. Holzmann T. Schmidt B. Hanses F. Epidemiology of SARS-CoV-2. Infection 2021 49 2 233 239 10.1007/s15010‑020‑01531‑3 33034020
    [Google Scholar]
  26. Sharifkashani S. Bafrani M.A. Khaboushan A.S. Pirzadeh M. Kheirandish A. Bali Y.H. Hessami A. Saghazadeh A. Rezaei N. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting. Eur. J. Pharmacol. 2020 884 173455 10.1016/j.ejphar.2020.173455 32745604
    [Google Scholar]
  27. Venkataraman S. Prasad B. Selvarajan R. RNA dependent rna polymerases: Insights from structure, function and evolution. Viruses 2018 10 2 76 10.3390/v10020076 29439438
    [Google Scholar]
  28. Ringvall M. Kjellén L. Mice deficient in heparan sulfate n-deacetylase/n-sulfotransferase 1. Prog. Mol. Bio. Trans. Sci. Zhang L. Academic Press 2010 35 58
    [Google Scholar]
  29. Alaoui L.H. Hassan O.U. Yang Y.W. Buchanan P. Lung cancer: Biology and treatment options. Biochim. Biophys. Acta 2015 1856 2 189 210 26297204
    [Google Scholar]
  30. Sabbula B.R. Gasalberti D.P. Anjum F. Squamous cell lung cancer. StatPearls. Internet StatPearls Publishing 2023
    [Google Scholar]
  31. Cersosimo R.J. Lung cancer: A review. Am. J. Health Syst. Pharm. 2002 59 7 611 642 10.1093/ajhp/59.7.611 11944603
    [Google Scholar]
  32. Zappa C. Mousa S.A. Non-small cell lung cancer: Current treatment and future advances. Transl. Lung Cancer Res. 2016 5 3 288 300 10.21037/tlcr.2016.06.07 27413711
    [Google Scholar]
  33. Rudin C.M. Brambilla E. Finn F.C. Sage J. Small-cell lung cancer. Nat. Rev. Dis. Primers 2021 7 1 3 10.1038/s41572‑020‑00235‑0 33446664
    [Google Scholar]
  34. Guarnera A. Santini E. Podda P. COVID-19 pneumonia and lung cancer: A challenge for the radiologist review of the main radiological features, differential diagnosis and overlapping pathologies. Tomography 2022 8 1 513 528 10.3390/tomography8010041 35202206
    [Google Scholar]
  35. Hammerschmidt S. Wirtz H. Lung cancer: Current diagnosis and treatment. Dtsch. Arztebl. Int. 2009 106 49 809 818 20038979
    [Google Scholar]
  36. Rai P. Kumar B.K. Deekshit V.K. Karunasagar I. Karunasagar I. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Appl. Microbiol. Biotechnol. 2021 105 2 441 455 10.1007/s00253‑020‑11061‑5 33394144
    [Google Scholar]
  37. Barsouk A. Saginala K. Aluru J.S. Rawla P. Barsouk A. US cancer screening recommendations: Developments and the impact of COVID-19. Med. Sci. (Basel) 2022 10 1 16 10.3390/medsci10010016 35323215
    [Google Scholar]
  38. Girard N. Deshpande C. Lau C. Finley D. Rusch V. Pao W. Travis W.D. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am. J. Surg. Pathol. 2009 33 12 1752 1764 10.1097/PAS.0b013e3181b8cf03 19773638
    [Google Scholar]
  39. Cryer A.M. Thorley A.J. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol. Ther. 2019 198 189 205 10.1016/j.pharmthera.2019.02.010 30796927
    [Google Scholar]
  40. Nooreldeen R. Bach H. Current and future development in lung cancer diagnosis. Int. J. Mol. Sci. 2021 22 16 8661 10.3390/ijms22168661 34445366
    [Google Scholar]
  41. Chu Z.G. Yang Z.G. Shao H. Zhu Z.Y. Deng W. Tang S.S. Chen J. Li Y. Small peripheral lung adenocarcinoma: CT and histopathologic characteristics and prognostic implications. Cancer Imaging 2011 11 1 237 246 22201671
    [Google Scholar]
  42. Toyoda Y. Nakayama T. Kusunoki Y. Iso H. Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br. J. Cancer 2008 98 10 1602 1607 10.1038/sj.bjc.6604351 18475292
    [Google Scholar]
  43. Casagrande G.M.S. Silva M.O. Reis R.M. Leal L.F. Liquid biopsy for lung cancer: Up-to-Date and perspectives for screening programs. Int. J. Mol. Sci. 2023 24 3 2505 10.3390/ijms24032505 36768828
    [Google Scholar]
  44. Halawa T. Baeesa S. Fadul M.M. Badahdah A.A. Enani M. Fathaddin A.A. Kawass D. Alkhotani A. Bahakeem B. Kurdi M. The role of liquid biopsy in the diagnosis and prognosis of WHO grade 4 astrocytoma. Cureus 2023 15 6 e41221 10.7759/cureus.41221 37525780
    [Google Scholar]
  45. Wadowska K. Lula B.I. Trembecki Ł. Mossoń S.M. Genetic markers in lung cancer diagnosis: A review. Int. J. Mol. Sci. 2020 21 13 4569 10.3390/ijms21134569 32604993
    [Google Scholar]
  46. Ammanagi A.S. Dombale V.D. Miskin A.T. Dandagi G.L. Sangolli S.S. Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man′s bronchoscopy!). Lung India 2012 29 1 19 23 10.4103/0970‑2113.92356 22345909
    [Google Scholar]
  47. Carr D.T. Cortese D.A. The value of cytologic examination in the management of lung cancer. Curr. Probl. Cancer 1980 5 4 20 34 10.1016/S0147‑0272(80)80009‑2
    [Google Scholar]
  48. Thunnissen F.B.J.M. Sputum examination for early detection of lung cancer. J. Clin. Pathol. 2003 56 11 805 810 10.1136/jcp.56.11.805 14600122
    [Google Scholar]
  49. Nicholson A.G. Tsao M.S. Beasley M.B. Borczuk A.C. Brambilla E. Cooper W.A. Dacic S. Jain D. Kerr K.M. Lantuejoul S. Noguchi M. Papotti M. Rekhtman N. Scagliotti G. Schil v.P. Sholl L. Yatabe Y. Yoshida A. Travis W.D. The 2021 WHO classification of lung tumors: Impact of advances since 2015. J. Thorac. Oncol. 2022 17 3 362 387 10.1016/j.jtho.2021.11.003 34808341
    [Google Scholar]
  50. Zhai P. Ding Y. Wu X. Long J. Zhong Y. Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int. J. Antimicrob. Agents 2020 55 5 105955 10.1016/j.ijantimicag.2020.105955 32234468
    [Google Scholar]
  51. Harrison A.G. Lin T. Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020 41 12 1100 1115 10.1016/j.it.2020.10.004 33132005
    [Google Scholar]
  52. Yüce M. Filiztekin E. Özkaya K.G. COVID-19 diagnosis —A review of current methods. Biosens. Bioelectron. 2021 172 112752 10.1016/j.bios.2020.112752 33126180
    [Google Scholar]
  53. Vandenberg O. Martiny D. Rochas O. Belkum v.A. Kozlakidis Z. Considerations for diagnostic COVID-19 tests. Nat. Rev. Microbiol. 2021 19 3 171 183 10.1038/s41579‑020‑00461‑z 33057203
    [Google Scholar]
  54. Peruski A.H. Peruski L.F. Jr Immunological methods for detection and identification of infectious disease and biological warfare agents. Clin. Diagn. Lab. Immunol. 2003 10 4 506 513 12853377
    [Google Scholar]
  55. Sheikhzadeh E. Eissa S. Ismail A. Zourob M. Diagnostic techniques for COVID-19 and new developments. Talanta 2020 220 121392 10.1016/j.talanta.2020.121392 32928412
    [Google Scholar]
  56. Racine R. Winslow G.M. IgM in microbial infections: Taken for granted? Immunol. Lett. 2009 125 2 79 85 10.1016/j.imlet.2009.06.003 19539648
    [Google Scholar]
  57. Andersson M.I. Carcamo A.C.V. Auckland K. Baillie J.K. Barnes E. Beneke T. Bibi S. Brooks T. Carroll M. Crook D. Dingle K. Dold C. Downs L.O. Dunn L. Eyre D.W. Jaramillo G.J. Harvala H. Hoosdally S. Ijaz S. James T. James W. Jeffery K. Justice A. Klenerman P. Knight J.C. Knight M. Liu X. Lumley S.F. Matthews P.C. McNaughton A.L. Mentzer A.J. Mongkolsapaya J. Oakley S. Oliveira M.S. Peto T. Ploeg R.J. Ratcliff J. Robbins M.J. Roberts D.J. Rudkin J. Russell R.A. Screaton G. Semple M.G. Skelly D. Simmonds P. Stoesser N. Turtle L. Wareing S. Zambon M. SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Res. 2020 5 181 10.12688/wellcomeopenres.16002.2 33283055
    [Google Scholar]
  58. Cozzi D. Bicci E. Bindi A. Cavigli E. Danti G. Galluzzo M. Granata V. Pradella S. Trinci M. Miele V. Role of chest imaging in viral lung diseases. Int. J. Environ. Res. Public Health 2021 18 12 6434 10.3390/ijerph18126434 34198575
    [Google Scholar]
  59. Parekh M. Donuru A. Balasubramanya R. Kapur S. Review of the chest CT differential diagnosis of ground-glass opacities in the covid era. Radiology 2020 297 3 E289 E302 10.1148/radiol.2020202504 32633678
    [Google Scholar]
  60. Ishfaq A. Farooq Y.S.M. Goraya A. Yousaf M. Gilani S.A. Kiran A. Ayoub M. Javed A. Bacha R. Role of high resolution computed tomography chest in the diagnosis and evaluation of COVID -19 patients -A systematic review and meta-analysis. Eur. J. Radiol. Open 2021 8 100350 10.1016/j.ejro.2021.100350 34007865
    [Google Scholar]
  61. Burrell C.J. Howard C.R. Murphy F.A. Laboratory diagnosis of virus diseases. Fenner and White's Medical Virology 2017 135 154 10.1016/B978‑0‑12‑375156‑0.00010‑2
    [Google Scholar]
  62. Burtscher C. Wuertz S. Evaluation of the use of PCR and reverse transcriptase PCR for detection of pathogenic bacteria in biosolids from anaerobic digestors and aerobic composters. Appl. Environ. Microbiol. 2003 69 8 4618 4627 10.1128/AEM.69.8.4618‑4627.2003 12902250
    [Google Scholar]
  63. Mo Y. Wan R. Zhang Q. Application of reverse transcription-PCR and real-time PCR in nanotoxicity research. Methods Mol. Biol. 2012 926 99 112 10.1007/978‑1‑62703‑002‑1_7 22975959
    [Google Scholar]
  64. Jyotsana N. King M.R. The impact of COVID-19 on cancer risk and treatment. Cell. Mol. Bioeng. 2020 13 4 285 291 10.1007/s12195‑020‑00630‑3 32837583
    [Google Scholar]
  65. Lotfi H. Mazar M.G. Ei N.M.H. Fahim M. Yazdi N.S. Vaccination is the most effective and best way to avoid the disease of COVID‐19. Immun. Inflamm. Dis. 2023 11 8 e946 10.1002/iid3.946 37647441
    [Google Scholar]
  66. Esposito G. Palumbo G. Carillio G. Manzo A. Montanino A. Sforza V. Costanzo R. Sandomenico C. Manna L.C. Martucci N. Rocca L.A. Luca D.G. Piccirillo M.C. Cecio D.R. Botti G. Totaro G. Muto P. Picone C. Normanno N. Morabito A. Immunotherapy in small cell lung cancer. Cancers 2020 12 9 2522 10.3390/cancers12092522 32899891
    [Google Scholar]
  67. Bodaghi A. Fattahi N. Ramazani A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon 2023 9 2 e13323 10.1016/j.heliyon.2023.e13323 36744065
    [Google Scholar]
  68. Dama E. Colangelo T. Fina E. Cremonesi M. Kallikourdis M. Veronesi G. Bianchi F. Biomarkers and lung cancer early detection: state of the art. Cancers 2021 13 15 3919 10.3390/cancers13153919 34359818
    [Google Scholar]
  69. Araghi M. Mannani R. maleki H.A. Hamidi A. Rostami S. Safa S.H. Faramarzi F. Khorasani S. Alimohammadi M. Tahmasebi S. Sigari A.R. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023 23 1 162 10.1186/s12935‑023‑02990‑y 37568193
    [Google Scholar]
  70. Chen S. Zhang J. Wang R. Luo X. Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010 70 1 63 70 10.1016/j.lungcan.2010.05.010 20541281
    [Google Scholar]
  71. Seijo L.M. Peled N. Ajona D. Boeri M. Field J.K. Sozzi G. Pio R. Zulueta J.J. Spira A. Massion P.P. Mazzone P.J. Montuenga L.M. Biomarkers in lung cancer screening: achievements, promises, and challenges. J. Thorac. Oncol. 2019 14 3 343 357 10.1016/j.jtho.2018.11.023 30529598
    [Google Scholar]
  72. Zhang C. Leighl N.B. Wu Y.L. Zhong W.Z. Emerging therapies for non-small cell lung cancer. J. Hematol. Oncol. 2019 12 1 45 10.1186/s13045‑019‑0731‑8 31023335
    [Google Scholar]
  73. Sève P. Dumontet C. Chemoresistance in non-small cell lung cancer. Curr. Med. Chem. Antican. Agen. 2005 5 1 73 88 10.2174/1568011053352604 15720263
    [Google Scholar]
  74. Dong S. Guo A.L. Chen Z.H. Wang Z. Zhang X.C. Huang Y. Xie Z. Yan H.H. Cheng H. Wu Y.L. RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J. Hematol. Oncol. 2010 3 1 10 10.1186/1756‑8722‑3‑10 20226083
    [Google Scholar]
  75. Mehta S. Shelling A. Muthukaruppan A. Lasham A. Blenkiron C. Laking G. Print C. Predictive and prognostic molecular markers for cancer medicine. Ther. Adv. Med. Oncol. 2010 2 2 125 148 10.1177/1758834009360519 21789130
    [Google Scholar]
  76. Šutić M. Vukić A. Baranašić J. Försti A. Džubur F. Samaržija M. Jakopović M. Brčić L. Knežević J. Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management. J. Pers. Med. 2021 11 11 1102 10.3390/jpm11111102 34834454
    [Google Scholar]
  77. Murray N. Coy P. Pater J.L. Hodson I. Arnold A. Zee B.C. Payne D. Kostashuk E.C. Evans W.K. Dixon P. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J. Clin. Oncol. 1993 11 2 336 344 10.1200/JCO.1993.11.2.336 8381164
    [Google Scholar]
  78. Travis W.D. The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the tnm classification of lung cancer. J Thorac Oncol. 2016 11 8 1204 1223
    [Google Scholar]
/content/journals/covid/10.2174/0126667975329337241224085220
Loading
A Mini Review on Effect of Corona Virus on Cancer Related to Lungs
Bentham Science Publishers ; https://doi.org/10.2174/0126667975329337241224085220
/content/journals/covid/10.2174/0126667975329337241224085220
/content/journals/covid/10.2174/0126667975329337241224085220
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: COVID-19 ; lung cancer ; infection, lung biome ; pandemic ; SARS-CoV-2 ; diagnosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test